Use of the Response Assessment in Neuro-Oncology (RANO) Criteria in Clinical Trials and Clinical Practice

Overview

Journal CNS Oncol

Specialty Oncology

Date 2019 Feb 27

PMID 30806082

Citations 119

Authors

Ugonma N Chukwueke

Patrick Y Wen

Affiliations

Soon will be listed here.

Citing Articles

Mapping glioma's impact on cognition: Insights from macrostructure, microstructure, and beyond.

Cayuela N, Izquierdo C, Vaquero L, Camara E, Bruna J, Simo M Neurooncol Adv. 2025; 7(1):vdaf003.

PMID: 39911704 PMC: 11795312. DOI: 10.1093/noajnl/vdaf003.

BRAF inhibitor monotherapy in BRAFV600E-mutated pediatric low-grade glioma: a single center's experience.

McThenia S, Reddy K, Damaraju E, Castellino E, He Z, Beers R Front Oncol. 2025; 14():1505951.

PMID: 39839763 PMC: 11747024. DOI: 10.3389/fonc.2024.1505951.

Identification of key elements in MRI reporting of intracranial meningiomas based on a nationwide survey of clinical experts in Germany.

Huckhagel T, Abboud T, Regelsberger J, Rieken S, Riedel C Sci Rep. 2025; 15(1):1043.

PMID: 39762278 PMC: 11704235. DOI: 10.1038/s41598-024-83737-1.

FET PET to differentiate between post-treatment changes and recurrence in high-grade gliomas: a single center multidisciplinary clinic controlled study.

Puranik A, Dev I, Rangarajan V, Jain Y, Patra S, Purandare N Neuroradiology. 2024; 67(2):363-369.

PMID: 39527264 PMC: 11893651. DOI: 10.1007/s00234-024-03495-9.

Feasibility of an artificial intelligence system for tumor response evaluation.

Xiuli N, Hua C, Peng G, Hairong Y, Meili S, Peng Y BMC Med Imaging. 2024; 24(1):280.

PMID: 39425045 PMC: 11488245. DOI: 10.1186/s12880-024-01460-9.

References

Reardon D, Ballman K, Buckner J, Chang S, Ellingson B . Impact of imaging measurements on response assessment in glioblastoma clinical trials. Neuro Oncol. 2014; 16 Suppl 7:vii24-35. PMC: 4195531. DOI: 10.1093/neuonc/nou286. View

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

Albert N, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim M . Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016; 18(9):1199-208. PMC: 4999003. DOI: 10.1093/neuonc/now058. View

Quant E, Wen P . Response assessment in neuro-oncology. Curr Oncol Rep. 2010; 13(1):50-6. DOI: 10.1007/s11912-010-0143-y. View

Ostrom Q, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C . CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol. 2017; 19(suppl_5):v1-v88. PMC: 5693142. DOI: 10.1093/neuonc/nox158. View

Wen P, Cloughesy T, Ellingson B, Reardon D, Fine H, Abrey L . Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro Oncol. 2014; 16 Suppl 7:vii36-47. PMC: 4195530. DOI: 10.1093/neuonc/nou226. View

Chakravarti A, Erkkinen M, Nestler U, Stupp R, Mehta M, Aldape K . Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res. 2006; 12(15):4738-46. DOI: 10.1158/1078-0432.CCR-06-0596. View

Chamberlain M, Junck L, Brandsma D, Soffietti R, Ruda R, Raizer J . Leptomeningeal metastases: a RANO proposal for response criteria. Neuro Oncol. 2017; 19(4):484-492. PMC: 5464328. DOI: 10.1093/neuonc/now183. View

McCoach C, Berge E, Lu X, Baron A, Camidge D . A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non-Small Cell Lung Cancer Clinical Trials: A Review of the ClinicalTrials.gov Trial Registry. J Thorac Oncol. 2016; 11(3):407-13. DOI: 10.1016/j.jtho.2015.10.024. View

10.

Alexander B, Lee E, Reardon D, Wen P . Current and future directions for Phase II trials in high-grade glioma. Expert Rev Neurother. 2013; 13(4):369-87. DOI: 10.1586/ern.12.158. View

11.

Lin N, Lee E, Aoyama H, Barani I, Barboriak D, Baumert B . Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015; 16(6):e270-8. DOI: 10.1016/S1470-2045(15)70057-4. View

12.

Warren K, Vezina G, Poussaint T, Warmuth-Metz M, Chamberlain M, Packer R . Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee. Neuro Oncol. 2017; 20(1):13-23. PMC: 5761545. DOI: 10.1093/neuonc/nox087. View

13.

van den Bent M, Vogelbaum M, Wen P, Macdonald D, Chang S . End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol. 2009; 27(18):2905-8. PMC: 2702230. DOI: 10.1200/JCO.2009.22.4998. View

14.

Huang R, Young R, Ellingson B, Veeraraghavan H, Wang W, Tixier F . Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment. Neuro Oncol. 2020; 22(12):1822-1830. PMC: 7746936. DOI: 10.1093/neuonc/noaa105. View

15.

Hamid O, Robert C, Daud A, Hodi F, Hwu W, Kefford R . Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013; 369(2):134-44. PMC: 4126516. DOI: 10.1056/NEJMoa1305133. View

16.

Gorlia T, Stupp R, Brandes A, Rampling R, Fumoleau P, Dittrich C . New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. Eur J Cancer. 2012; 48(8):1176-84. DOI: 10.1016/j.ejca.2012.02.004. View

17.

Berghoff A, Brastianos P . Toward Precision Medicine in Brain Metastases. Semin Neurol. 2018; 38(1):95-103. DOI: 10.1055/s-0038-1627469. View

18.

Avila E, Chamberlain M, Schiff D, Reijneveld J, Armstrong T, Ruda R . Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. Neuro Oncol. 2016; 19(1):12-21. PMC: 5193028. DOI: 10.1093/neuonc/now190. View

19.

Lin N, Lee E, Aoyama H, Barani I, Baumert B, Brown P . Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol. 2013; 14(10):e396-406. DOI: 10.1016/S1470-2045(13)70311-5. View

20.

Okada H, Weller M, Huang R, Finocchiaro G, Gilbert M, Wick W . Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015; 16(15):e534-e542. PMC: 4638131. DOI: 10.1016/S1470-2045(15)00088-1. View